Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease

A number of studies have now been conducted confirming the relationship between arterial hypertension (AH) and nonalcoholic fatty liver disease (NAFLD). It has been proved that the presence of AH increases or provokes the development of NAFLD. A study of telmisartan effectiveness in combination with atorvastatin and ursodeoxycholic acid (UDCA) in patients with AH and NAFLD was carried out in this article. Material and methods. The study included 39 patients diagnosed with arterial hypertension in combination with NAFLD, who were treated with a combination of drugs: Telmisartan, Atorvastatin and UDCA for 12 weeks. The comparison group consisted of 33 patients with NAFLD who received basic NAFLD therapy without telmisartan and atorvastatin. The study analyzed the efficacy of the prescription of this combination on the clinical condition of patients with AH combined with NAFLD, their hemodynamic parameters, the levels of blood lipid spectrum, IL-6, leptin, adiponectin, and the dynamics of echocardiographic and ultrasonographic parameters. Results and discussion. It has been revealed, that application of telmisartan, atorvastatin and UZHK combination for 12 weeks significantly reduced BP levels to the target values, improved hemodynamic indexes, led to reduction of atherogenic components of blood lipid spectrum. And also prescription of this combination decreased IL-6 and leptin levels, increased adiponectin content, which contributed to improvement of the general state of patients, decrease in the severity of clinical and functional manifestations of NAFLD.

1. Qian L.-Y., Tu J.-F., Ding Y.-H., Pang J., Che X.-D., Zou H., Huang D.-S. Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population. Normal is not the new normal. Medicine (Baltimore). 2016; 95 (29): e4293. doi: 10.1097/MD.0000000000004293

2. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84. doi: 10.1002/hep.28431

3. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018; 15 (1): 11–20. doi: 10.1038/nrgastro.2017.109

4. Federico A., Dallio M., Masarone M., Persico M., Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction. Eur. Rev. Med. Pharmacol. Sci. 2016; 20 (22): 4731–4741.

5. Shishova I.A., Abdulgani Sh., Efremova О.A., Bolkhovitin A.A., Kamyshnikova L.A., Chernobai P.E. Genetic factors of nonalcoholic fatty liver disease against metabolic syndrome. University science: a look into the future: proc. conf., Kursk, 07.02.2020. Kursk: KGMU, 2020. 393–395. [In Russian].

6. Rosato V., Masarone M., Dallio M., Federico A., Aglitti A., Persico M. NAFLD and Extra-Hepatic Comorbidities: Current evidence on a multi-organ metabolic syndrome. J. Environ. Res. Public. Health. 2019; 16 (18): 3415. doi: 10.3390/ijerph16183415

7. Zhao Y.-C., Zhao G.-J., Chen Z., She Z.-G., Cai J., Li H. Nonalcoholic fatty liver disease an emerging driver of hypertension. Hypertension. 2020; 75 (2): 275–284. doi: 10.1161/HYPERTENSIONAHA.119.13419

8. Satou R., Penrose H., Navar L.G. Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr. Hypertens. Rep. 2018; 20: 100. doi: 10.1007/s11906-018-0900-0

9. Statsenko M.E., Streltsova A.M., Turovets M.I. Effect of nonalcoholic fatty liver disease on arterial stiffness and risk of cardiovascular complications in patients with arterial hypertension. Arkhiv vnutrnney meditsiny = Archives of Internal Medicine. 2020; 10 (4): 296–304. [In Russian]. doi: 10.20514/2226-6704-2020-10-4-296-304

10. Goh G.B., Pagadala M.R., Dasarathy J., Unalp-Arida A., Sargent R., Hawkins C., Sourianarayanane A., Khiyami A., Yerian L., Pai R., McCullough A.J., Dasarathy S. Renin-angiotensin system and fibrosis in nonalcoholic fatty liver disease. Liver Int. 2015; 35: 979–985. doi: 10.1111/liv.12611

11. Omboni S., Volpe M. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. Cardiovasc. Ther. 2018; 6 (6): e12471. doi: 10.1111/1755-5922.12471

12. Lucas F.A., Signe S.T., Kirsten M., Boye L.J. Role of the renin-angiotensin system in kidney development and programming of adult blood pressure. Review Clin. Sci. (Lond) 2020; 134(6): 641–656. doi: 10.1042/CS20190765

13. Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S., Teo K., Anderson C., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372 (9644): 1174–1183. doi: 10.1016/S0140-6736(08)61242-8

14. Tikhonov A.I., Hvorostinka V.N., Efremova O.A., Yarnikh T.G., Pushkar S.N., Kotenko A.M. The remedy that has antioxidant and hepatoprotective properties. Patent RF № 2020946, 15.10.1994. [In Russian].

15. Bakheit A.H., Abdelgalil A.A., Mustafa B., Haque A., Wani T.A. Telmisartan. Profiles drug. Subst. Excip. Relat. Methodol. 2015; 40: 371–429. doi: 10.1016/bs.pdrm.2015.01.003

16. Ogawa H., Soejima H., Matsui K., Kim-Mitsuyama S., Yasuda O., Node K., Yamamuro M., Yamamoto E., Kataoka K., Jinnouchi H., Sekigami T., ATTEMPT-CVD investigators. A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study. Eur. J. Prev. Cardiol. 2016; 23 (9): 913–921. doi: 10.1177/2047487315603221

17. Pérez-Pérez A., Vilariño-García T., Fernández-Riejos P., Martín-González J., Segura-Egea J.J., Sánchez-Margalet V. Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev. 2017; 35: 71–84. doi: 10.1016/j.cytogfr.2017.03.001

18. Borém L.M.A., Neto J.F.R., Brandi I.V., Lelis D.F., Santos S.H.S. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens. Res. 2018; 41 (6): 394–405. doi: 10.1038/s41440-018-0040-6

19. Shahinul A., Jahangir K., Golam M., Utpal-Das G., Nazmul H., Khorshed A. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Randomized controlled trial. Saudi J. Gastroenterol. 2016; 22 (1): 69–76. doi: 10.4103/1319-3767.173762

20. Devan A.R., Nair B., Kumar A.R., Nath L.R. An insight into the role of telmisartan as PPAR-γ/α dual activator in the management of nonalcoholic fatty liver disease. Review Biotechnol. Appl. Biochem. 2021; 2 (12). doi: 10.1002/bab.2123

21. Hirata T., Tomita K., Kawai T., Yokoyama H., Shimada A., Kikuchi M., Hirose H., Ebinuma H., Irie J., Ojiro K., Oikawa Y., Saito H., Itoh H., Hibi T. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: fatty liver protection trial by telmisartan or losartan study (FANTASY). J. Endocrinol. 2013; 2013: 587140. doi: 10.1155/2013/587140

22. Ivashkin V.T., Mayevskaya M.V., Pavlov Ch.S., Tikhonov I.N., Shirokova E.N., Bueverov A.O., Drapkina O.M., Shulpekova Yu.O., Tsukanov V.V., Mammaev S.N., Maev I.V., Palgova L.K. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 2 (26): 24–42. doi: 10.22416/1382-4376-2016-26-2-24-42

23. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman J.M., De B.G.G., Delgado V., Ference B.A., Graham Ia.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O. 2019ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25 (5): 121–193. [In Russian]. doi: 10.15829/1560-4071-2020-3826

24. Dicheva D.T., Kuznetsova E.I. Modern aspects of treatment of patients with nonalcoholic fatty liver disease. Consilium Medicum. 2018; 20 (8): 20–23. [In Russian]. doi: 10.26442/2075-1753_2018.8.20-23

25. Bakulin I.G., Medvedev Yu.V. 13C-metacetin breathing test in assessing the functional reserve of the liver. Farmateka = Pharmateca. 2016; 16 (5): 71–80. [In Russian].

26. Gorowska-Kowolik K., Chobot A., Kwiecien J. 13C Methacetin breath test for assessment of microsomal liver function: methodology and clinical application. Gastroenterol. Res. Pract. 2017; 7397840. doi: 10.1155/2017/7397840

27. Yu W., Kun L.M., Yang Z., Yi W., Gui H.W., Ze B.H., Liang L., Jian L., Pei P.C., Xiong Z.R., Bi C.L. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease. Liver Int. 2016; 36 (10): 1525–1534. doi: 10.1111/liv.13131

28. Spurná J., Karásek D., Kubíčková V., Goldmannová D., Krystyník O., Schovánek J., Zadražil J. Relationship of selected adipokines with markers of vascular damage in patients with type 2 diabetes. Metab. Syndr. Relat. Disord. 2018; 16 (5): 246–253. doi: 10.1089/met.2017.0179

29. Dong X., Yan X., Zhang W., Tang S. Adiponectin enhances biological functions of vascular endothelial progenitor cells through the mTOR-STAT3 signaling pathway. Physiol. Res. 2018; 67 (4): 563–570. doi: 10.33549/physiolres.933738